1. Search Result
Search Result
Results for "

FGFR

" in MedChemExpress (MCE) Product Catalog:

202

Inhibitors & Agonists

3

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

3

Peptides

6

Inhibitory Antibodies

6

Natural
Products

71

Recombinant Proteins

15

Isotope-Labeled Compounds

7

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148779

    FGFR Cancer
    FGFR3-IN-5 is a potent and selective FGFR3 inhibitor with IC50 values of 3, 44, and 289 nM for FGFR3, FGFR2, and FGFR1, respectively. FGFR3-IN-5 can be used in research of cancer .
    <em>FGFR</em>3-IN-5
  • HY-156790

    FGFR Cancer
    FGFR3-IN-6 is a potent and selective FGFR3 inhibitor with IC50 value less than 350 nM. FGFR3-IN-6 can be used in research of cancer .
    <em>FGFR</em>3-IN-6
  • HY-156791

    FGFR Cancer
    FGFR3-IN-7 is a potent and selective FGFR3 inhibitor with IC50 value less than 350 nM. FGFR3-IN-7 can be used in research of cancer .
    <em>FGFR</em>3-IN-7
  • HY-163273

    FGFR Cancer
    FGFR4-IN-17 (Compound (S)-23) is a piperazinyl diflurindan derivative containing pyridinyl. FGFR4-IN-17 is a FGFR inhibitor with IC50 values of 24.2, 16.1, 78.0, and 68.0 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FGFR4-IN-17 has antitumor activity .
    <em>FGFR</em>4-IN-17
  • HY-147619

    FGFR Cancer
    FGFR-IN-4 is a potent inhibitor of FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2022033532A1, compound 20) . FGFR-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>FGFR</em>-IN-4
  • HY-147620

    FGFR Cancer
    FGFR-IN-5 is a potent inhibitor of FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2022042612A1, compound 3) . FGFR-IN-5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>FGFR</em>-IN-5
  • HY-163527

    FGFR Cancer
    FGFR-IN-13 (compound III-30) is an irreversible covalent fibroblast growth factor receptor (FGFR) inhibitor. FGFR-IN-13 regulates endogenous FGFR1(IC50 = 0.20 ± 0.02 nM) and FGFR4(IC50 = 0.40 ± 0.03 nM) mediated signaling pathways by inhibiting the expression of key proteins. FGFR-IN-13 inhibits total-PARP and Bcl-2 protein expressions, and promote Cleaved-PARP and Bax protein expressions in a dose-dependent manner. FGFR-IN-13 has significant antitumor activity and oral activity .
    <em>FGFR</em>-IN-13
  • HY-147684

    FGFR Neurological Disease
    FGFR-IN-7 (compound 17) is an orally active, potent and BBB-penetrated FGFR (fibroblast growth factor receptor) modulator. FGFR-IN-7 shows neuroprotective activity. FGFR-IN-7 improves brain exposure and reduced risk of phospholidosis. FGFR-IN-7 can be used for neurodegenerative diseases research .
    <em>FGFR</em>-IN-7
  • HY-147683

    FGFR Neurological Disease
    FGFR-IN-3 (compound 6) is an orally active, potent and BBB-penetrated FGFR (fibroblast growth factor receptor) modulator. FGFR-IN-3 shows neuroprotective activity. FGFR-IN-3 can be used for neurodegenerative diseases research .
    <em>FGFR</em>-IN-3
  • HY-142921

    FGFR Cancer
    FGFR-IN-2 (compound 1) is a potent FGFR inhibitor with IC50s of 7.3 nM, 4.3 nM, 7.6 nM, 11 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-2 has the potential for cancer research .
    <em>FGFR</em>-IN-2
  • HY-145043

    FGFR Cancer
    FGFR-IN-1 is a potent FGFR inhibitor with an IC50 of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219) .
    <em>FGFR</em>-IN-1
  • HY-146541

    FGFR Cancer
    FGFR4-IN-10 (compound 5a) is a potent and selective FGFR4 inhibitor with an IC50 value of 70.7 nM. FGFR4-IN-10 shows no inhibition against other FGFR family members, i.e. FGFR1, FGFR2 and FGFR3 .
    <em>FGFR</em>4-IN-10
  • HY-152104

    FGFR Cancer
    FGFR-IN-9 (Compound 19) is a potent, reversible and orally active FGFR inhibitor with an IC50 of 17.1, 29.6, 30.7, 46.7 and 64.3 nM against FGFR4 WT, FGFR3, FGFR4 V550L, FGFR2 and FGFR1, respectively .
    <em>FGFR</em>-IN-9
  • HY-155028

    FGFR Cancer
    FGFR-IN-11 (compound I-5) is an orally active and covalent FGFR inhibitor with IC50 values of 9.9 nM (FGFR1), 3.1 nM (FGFR2), 16 nM (FGFR3), and 1.8 nM (FGFR4), respectively. FGFR-IN-11 inhibits multiple cancer cell proliferation with nanomolar activity. FGFR-IN-11 inhibits tumor growth significantly in xenograft mice models .
    <em>FGFR</em>-IN-11
  • HY-148778

    FGFR Cancer
    FGFR3-IN-4 is a selective FGFR3 inhibitor, with an IC50 value of less than 50 nM. FGFR3-IN-4 is at least 10 fold more selective for FGFR3 than for FGFR1 .
    <em>FGFR</em>3-IN-4
  • HY-145231

    FGFR Cancer
    FGFR2-IN-2 (Compound 38) is a selective FGFR2 inhibitor with IC50s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively .
    <em>FGFR</em>2-IN-2
  • HY-147793

    FGFR Cancer
    FGFR4-IN-12 (Compound A34) is a potent inhibitor of FGFR4. FGFR4-IN-12 exhibits improved FGFR4 inhibitory capability and selectivity and excellent anti-proliferative activities against FGFR4-dependent HCC cell lines. FGFR4-IN-12 has the potential for the research of cancer diseases . FGFR4-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>FGFR</em>4-IN-12
  • HY-115902

    FGFR Apoptosis Cancer
    FGFR4-IN-7 (Compound C3) is a covalent reversible FGFR4 inhibitor with an IC50 value of 0.42 μM. FGFR4-IN-7 induces apoptosis via the FGFR4 signaling pathway blockage. FGFR4-IN-7 can be used for the research of hepatocellular carcinoma (HCC) .
    <em>FGFR</em>4-IN-7
  • HY-147515

    FGFR Cancer
    FGFR4-IN-11 (Compound 30) is a potent, selective, covalent FGFR4 inhibitor with an IC50 of 2.1 nM. FGFR4-IN-11 significantly inhibits the FGF19/FGFR4 signaling pathway and shows antitumor activity .
    <em>FGFR</em>4-IN-11
  • HY-156704

    FGFR Cancer
    FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of FGFR-4 for cancer research .
    <em>FGFR</em>4-IN-16
  • HY-151903S

    FGFR Cancer
    FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC50s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC50s of 2.7 nM and 6.1 nM, respectively[1].
    <em>FGFR</em>2/3-IN-1
  • HY-145836

    FGFR Cancer
    FGFR4-IN-8 (Compound 7v) is an ATP-competitive, highly selective covalent inhibitor of wild-type and gatekeeper mutant FGFR4. FGFR4-IN-8 exhibits excellent potency against FGFR4, FGFR4 V550L, FGFR4 V550M and FGFR4 C552S with IC50s of 0.5, 0.25, 1.6, 931 nM, respectively. FGFR4-IN-8 exhibits potent antiproliferative activity against Hep3B hepatocellular carcinoma cells with the IC50 value of 29 nM. FGFR4-IN-8 demonstrates modest in vivo antitumor efficacy in nude mice bearing the Huh-7 xenograft model .
    <em>FGFR</em>4-IN-8
  • HY-150652

    FGFR Apoptosis Cancer
    FGFR-IN-8 (Compound 17a) is a highly potent and orally active panFGFR inhibitor against wild-type and mutant FGFRs. FGFR-IN-8 shows inhibition with IC50 values of <0.5, 189.1, <0.5, 22.6, <0.5 and 7.30 nM against FGFR1, V564F-FGFR2, N549H-FGFR2, V555M-FGFR3, FGFR3 and FGFR4, respectively. GFR-IN-8 induces cancer cell apoptosis and shows anticancer activities .
    <em>FGFR</em>-IN-8
  • HY-147714

    FGFR VEGFR Cancer
    FGFR3-IN-2 (compound 18b) is a potent and selective FGFR3 inhibitor, with IC50s of 4.1 nM and 570 nM for FGFR3 and VEGFR2, respectively. FGFR3-IN-2 can be used for the research of bladder cancer .
    <em>FGFR</em>3-IN-2
  • HY-144759

    FGFR Cancer
    FGFR4-IN-9 (Compound 6O) is a selective FGFR4 inhibitor with an IC50 of 75.3 nM. FGFR4-IN-9 effectively inhibits both the growth and angiogenesis of HCC .
    <em>FGFR</em>4-IN-9
  • HY-145230

    FGFR Others
    FGFR2-IN-1 is a selective FGFR2 inhibitor with an IC50 of 140 nM.
    <em>FGFR</em>2-IN-1
  • HY-147713

    FGFR Cancer
    FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor, with IC50s of 40 nM, 5.1 nM, and 12 nM for FGFR1, 2, and 3, respectively. FGFR3-IN-1 can be used for the research of bladder cancer .
    <em>FGFR</em>3-IN-1
  • HY-155046

    FGFR Cancer
    FGFR4-IN-14 (Compound 27i) is a FGFR4 inhibitor (IC50: 2.4 nM. FGFR4-IN-14 inhibits the proliferation of V550L and N535K mutant strains, with IC50s of 21 nM, 2.5 nM, 171 nM against huh7, BaF3/ETV6-FGFR4-V550L and BaF3/ETV6-FGFR4-N535K cells respectively. FGFR4-IN-14 has potent antitumor efficacy in the Huh7 xenograft model. FGFR4-IN-14 can be used for research of hepatocellular carcinoma (HCC) .
    <em>FGFR</em>4-IN-14
  • HY-158248

    FGFR Cancer
    FGFR4-IN-19 (compound 8B) is a potent covalent fibroblast growth factor receptor 4 (FGFR4) inhibitor (IC50=1.2 nM). FGFR4-IN-19 achieves high efficiency and isotype selectivity by covalently targeting a rare cysteine (C552) in the FGFR4 kinase domain. FGFR4-IN-19 can be used for hepatocellular carcinoma (HCC) research .
    <em>FGFR</em>4-IN-19
  • HY-100631

    FGFR Neurological Disease
    FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 0.7 nM.
    <em>FGFR</em>4-IN-1
  • HY-158010

    FGFR Cancer
    FGFR3-IN-8 (example91) is a selective FGFR3 inhibitor .
    <em>FGFR</em>3-IN-8
  • HY-158011

    FGFR Cancer
    FGFR3-IN-9 (example27) is a selective FGFR3 inhibitor .
    <em>FGFR</em>3-IN-9
  • HY-147715

    FGFR Cancer
    FGFR3-IN-3 (compound 40a) is a potent and pan-FGFR inhibitor, with IC50s of 2.1 nM, 3.1 nM, 4.3 nM and 74 nM for FGFR1, 2, 3, and 4, respectively. FGFR3-IN-3 can be used for the research of bladder cancer .
    <em>FGFR</em>3-IN-3
  • HY-131704

    FGFR Cancer
    FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research .
    <em>FGFR</em>4-IN-5
  • HY-149487

    FGFR Cancer
    FGFR1 inhibitor-8 (Compound 9) is a FGFR1 inhibitor (IC50s: 0.5 nM). FGFR1 inhibitor-8 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-8 has anticancer activity .
    <em>FGFR</em>1 inhibitor-8
  • HY-149488

    FGFR Cancer
    FGFR1 inhibitor-9 (Compound 7) is an FGFR1 inhibitor (IC50s: 0.85 nM). FGFR1 inhibitor-9 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-9 has anticancer activity .
    <em>FGFR</em>1 inhibitor-9
  • HY-162283

    FGFR Cancer
    FGFR4-IN-18 (compound 8z) is an inhibitor of FGFR4 and can be used in cancer research .
    <em>FGFR</em>4-IN-18
  • HY-156019

    FGFR Cancer
    FGFR1 inhibitor-10 (Compound 4i) is an FGFR1 inhibitor (IC50: 28 nM). FGFR1 inhibitor-10 inhibits the phosphorylation of FGFR1. FGFR1 inhibitor-10 has anti-angiogenic, anti-invasion activity, and anti-tumor effect .
    <em>FGFR</em>1 inhibitor-10
  • HY-143881

    FGFR Cancer
    FGFR4-IN-6 (Compound 9ka) is a covalently reversible FGFR4 inhibitor with an IC50 value of 5.4 nM. FGFR4-IN-6 also exhibits good oral pharmacokinetic properties. FGFR4-IN-6 induces significant tumor regressions in a xenograft mouse model of Hep3B2.1-7 HCC cell line without an obvious sign of toxicity . FGFR4-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>FGFR</em>4-IN-6
  • HY-160013

    FGFR Cancer
    FGFR-IN-12 (example 14), a pyrimidinyl aryl urea derivative, is a potent FGFR inhibitor .
    <em>FGFR</em>-IN-12
  • HY-129181

    FGFR Cancer
    FGFR4-IN-4 (compound 693) is a FGFR4 inhibitor with anti-tumor activity, extracted from patent WO2018113584A1 .
    <em>FGFR</em>4-IN-4
  • HY-147621

    FGFR Cancer
    FGFR-IN-6 (Compound 5) is a FGFR inhibitor . FGFR-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>FGFR</em>-IN-6
  • HY-149512

    FGFR VEGFR Cancer
    FGFR1/VEGFR2-IN-1 (compound 2b) is an FGFR1/VEGFR2 inhibitor. FGFR1/VEGFR2-IN-1 can be used for cancer research .
    <em>FGFR</em>1/VEGFR2-IN-1
  • HY-148597

    FGFR Cytochrome P450 Cancer
    FGFR-IN-10 is an orally active inhibitor of FGFR and Cytochrome P450 (CYPs). FGFR-IN-10 inhibits wide type and V564F mutant FGFR2 with IC50s of 104.1 nM and 43.6 nM, respectively. FGFR-IN-10 also inhibits CYPs with IC50s of 3.33 μM (CYP2C9), 18.75 μM (CYP2C19), 4.34 μM (CYP2CD6), and 0.69 μM (CYP3A4), respectively .
    <em>FGFR</em>-IN-10
  • HY-143272

    FGFR Cancer
    FGFR1 inhibitor-6 is a potent FGFR1 inhibitor with an IC50 value of 16.31 nM. FGFR1 inhibitor-6 shows cytotoxic activities. FGFR1 inhibitor-6 induces apoptosis and cell cycle arrest at pre-G1 and G2/M phase .
    <em>FGFR</em>1 inhibitor-6
  • HY-139376

    FGFR Cancer
    FGFR1 inhibitor-2 is a FGFR1 inhibitor (IC50 is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer .
    <em>FGFR</em>1 inhibitor-2
  • HY-158098

    FGFR Metabolic Disease
    FGFR1 inhibitor-11 (compound 5g) binds to FGFR1, inactivation of its downstream ERK1/2 and IκBα/NF-κB signaling inhibited RANKL-induced osteoclastogenesis. FGFR1 inhibitor-11 has oral bioactivity .
    <em>FGFR</em>1 inhibitor-11
  • HY-15813

    FGFR irreversible inhibitor-1

    FGFR Cancer
    FIIN-1 is a potent, irreversible, selective FGFR inhibitor. FIIN-1 binds to FGFR1/2/3/4 and Flt1/4 with Kds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC50s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively .
    FIIN-1
  • HY-149486

    FGFR Cancer
    FGFR1 inhibitor 7 (compound 5) is an inhibitor of FGFR1 Tyrosine Kinase with IC50 value of 0.33 nM. FGFR1 inhibitor 7 shows broad-spectrum cytotoxicity agasinst human cancer cell lines, and inhibits MOLT3 cells with IC50 of 2.1 μM .
    <em>FGFR</em>1 inhibitor 7
  • HY-114311

    FGFR Discoidin Domain Receptor Cancer
    FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity .
    <em>FGFR</em>1/DDR2 inhibitor 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: